Viral load testing is a key indicator for assessing ART success and diagnosing drug resistance in people living with HIV/AIDS on antiretroviral therapy. This study aimed to assess virological suppression among people living with HIV / AIDS on antiretroviral therapy in Guinea. This was a three years descriptive cross-sectional that involved adult HIV-positive patients treated in different sites in Conakry. The study population consisted of patients living with HIV/AIDS, followed up at Conakry ART care and treatment sites, samples collected from the study population were sent to the National Institute of Public Health for viral load testing between January 2018 and June 2021. The viral load was quantified by the Generic Biocentric technique and the detection threshold set at 350 copies/ml. Factors associated with virological suppression were analysed by univariate or multivariate logistic regression. Statistical analysis were performed by R software version R4.0.3. A total of 9815 samples were collected and viral load data analyzed at the national public health laboratory. The sample was dominated by women (72%), with an average age of 29. Of these, 6,706 (68%) of people on ART had viral load suppression. The univaried analysis showed that women were (22%) more likely to have VL suppression (p-value < 0.001) moreover, the chance for all HIV-positive people on treatment to achieve viral load suppression was related to the length of treatment. The results of this study show viral load suppression greater than 68%. The length of antiretroviral therapy, female gender, and advancing age of PLHIV were associated with VL suppression. Targeted awareness raising actions must be undertaken with patients who have an important risk.
| Published in | Central African Journal of Public Health (Volume 8, Issue 2) |
| DOI | 10.11648/j.cajph.20220802.11 |
| Page(s) | 22-27 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2024. Published by Science Publishing Group |
Factors Associated, Virological Suppression, Antiretroviral Therapy, Conakry, Guinee
| [1] | Bvochora T, Satyanarayana S, Takarinda KC, Bara H, Chonzi P, Komtenza B, et al. Enhanced adherence counselling and viral load suppression in HIV seropositive patients with an initial high viral load in Harare, Zimbabwe: Operational issues. Mor O, editor. PLOS ONE. 2019 Feb 5; 14 (2): e0211326. |
| [2] | Touré A, Cissé D, Kadio Kjjo, Camara A, Traoré Fa, Delamou A, et al. Facteurs associés aux perdus de vue des patients sous traitement antirétroviral dans un centre de traitement ambulatoire du VIH à Conakry, Guinée. Rev DÉpidémiologie Santé Publique. 2018 Jul; 66 (4): 273–9. |
| [3] | INSP. OPPE-ARA Mettre fin au VIH/SIDA par un meilleur suivi des patients: Accelérer l’accès et l et l’utilisation de la charge virale [Internet]. 2019 Juillet p. 4. Available from: https://www.insp-guinee.org/wp-content/uploads/2019/08/SOLTHIS_OPP-ERA_brochure-GUINEE-A4_web.pdf. |
| [4] | Institut National de la Statitique, Ministere du plan et du development Economique, Conakry, Guinée. Enquete Demographique et de Sante (EDS), 2018. 2019 Juillet p. 650. Report No.: V. |
| [5] | Kitchen PJ, Bärnighausen K, Dube L, Mnisi Z, Dlamini-Nqeketo S, Johnson CC, et al. Expansion of HIV testing in Eswatini: stakeholder perspectives on reaching the first 90. Afr J AIDS Res. 2020 Jul 2; 19 (3): 186–97. |
| [6] | ONUSIDA. Rapport mondial d’avancement sur la lutte contre le sida 2020, en Guinée [Internet]. ONUSIDA-GUINEE; 2020 p. 47. Available from: https://www.unaids.org/sites/default/files/country/documents/GIN_2020_countryreport.pdf. |
| [7] | Kone F, Toni T d’Aquin, Ouassa T, Menan H, Ebegui D, Diallo K, et al. Mesure de l’ARN VIH-1 et du taux de lymphocytes TCD4 dans le suivi du traitement antirétroviral de patients infectés par le VIH en Côte d’Ivoire. Int J Biol Chem Sci. 2019 Sep 6; 13 (3): 1343. |
| [8] | UNAIDS, New global commitment to defeat AIDS by 2030; https://cotedivoire.un.org/fr/130820-nouvel-engagement-mondial-pour-vaincre-le-sida-dici-2030. |
| [9] | Diouara AAM, Ndiaye HD, Guindo I, Bangoura N, Cissé M, Edmond T, et al. Antiretroviral treatment outcome in HIV-1-infected patients routinely followed up in capital cities and remote areas of Senegal, Mali and Guinea-Conakry. J Int AIDS Soc. 2014 Jan; 17 (1): 19315. |
| [10] | CNLS. Cadre Stratégique National de Lutte les IST/VIH/Sida 2013-2017 [Internet]. 2012 p. 97. Available from: https://www.childrenandaids.org/sites/default/files/2018-05/Guinea_Nat%20Stat%20Framework%20HIV_2013-2017%20fr.pdf. |
| [11] | Somparé AW. La politique et les pratiques de santé en Guinée à l’épreuve de l’épidémie d’Ebola: le cas de la ville de Conakry in Lien Social et Politiques, n. 78, 2017. Erudit. 2017; 19. |
| [12] | WHO. Normes et protocoles de prise en charge de l’infection par le VIH chez l’adulte et l’enfant en GUINEE [Internet]. 2005. Available from: https://www.who.int/hiv/pub/guidelines/guinea_art.pdf. |
| [13] | Elyse Poitras et Alain Houde. La PCR en temps réel: principes et applications. Reviews in Biology and BiotechnologyBy The Moroccan Society of Biology in Canada. 2002 Dec 2; 11. |
| [14] | Drain PK, Dorward J, Bender A, Lillis L, Marinucci F, Sacks J, et al. Point-of-Care HIV Viral Load Testing: an Essential Tool for a Sustainable Global HIV/AIDS Response. Clin Microbiol Rev [Internet]. 2019 Jun 19 [cited 2021 Jul 16]; 32 (3). Available from: https://journals.asm.org/doi/10.1128/CMR.00097-18. |
| [15] | Eisinger RW, Dieffenbach CW, Fauci AS. HIV Viral Load and Transmissibility of HIV Infection: Undetectable Equals Untransmittable. JAMA. 2019 Feb 5; 321 (5): 451. |
| [16] | Ba S, Dia Badiane NM, Hawes S, Deguenonvo LF, Sall F, Ndour CT, et al. Infection à VIH-2 au Sénégal: échecs virologiques et résistances aux antirétroviraux (ARV). Pan Afr Med J [Internet]. 2019 [cited 2021 Aug 21]; 33. Available from: http://www.panafrican-med-journal.com/content/article/33/222/full/. |
| [17] | Arkell C., Perez E. Le traitement du VIH et la charge virale indétectable pour prévenir la transmission du VIH. 2021; Available from: https://www.catie.ca/fr/feuillets-info/transmission/vih-charge-virale-traitement-transmission-sexuelle. |
| [18] | Nosyk B, Montaner JSG, Colley G, Lima VD, Chan K, Heath K, et al. The cascade of HIV care in British Columbia, Canada, 1996–2011: a population-based retrospective cohort study. Lancet Infect Dis. 2014 Jan; 14 (1): 40–9. |
| [19] | Kiweewa F, Esber A, Musingye E, Reed D, Crowell TA, Cham F, et al. HIV virologic failure and its predictors among HIV-infected adults on antiretroviral therapy in the African Cohort Study. Menéndez-Arias L, editor. PLOS ONE. 2019 Feb 5; 14 (2): e0211344. |
| [20] | Ndembi N, Murtala-Ibrahim F, Tola M, Jumare J, Aliyu A, Alabi P, et al. Predictors of first-line antiretroviral therapy failure among adults and adolescents living with HIV/AIDS in a large prevention and treatment program in Nigeria. AIDS Res Ther. 2020 Dec; 17 (1): 64. |
| [21] | Ssempijja V, Nakigozi G, Chang L, Gray R, Wawer M, Ndyanabo A, et al. Rates of switching to second-line antiretroviral therapy and impact of delayed switching on immunologic, virologic, and mortality outcomes among HIV-infected adults with virologic failure in Rakai, Uganda. BMC Infect Dis. 2017 Dec; 17 (1): 582. |
| [22] | Beaudrap PD, Thiam M, Diouf A, Toure-Kane C, Ngom-Guèye NF, Mboup S, et al. Risk of Virological Failure and Drug Resistance During First and Second-Line Antiretroviral Therapy in a 10-Year Cohort in Senegal: Results From the ANRS 1215 Cohort. J Acquir Immune Defic Syndr. 2013; 62 (4): 7. |
| [23] | Ford N, Orrell C, Shubber Z, Apollo T, Vojnov L. HIV viral resuppression following an elevated viral load: a systematic review and meta-analysis. J Int AIDS Soc [Internet]. 2019 Nov. [cited 2021 [Jul 14]; 22 (11). Available from: https://onlinelibrary.wiley.com/doi/10.1002/jia2.25415. |
APA Style
Alimou Camara, Penda Maladho Diallo, Mamadou Bobo Diallo, Talla Nioké, Adama Cissé, et al. (2022). Factors Associated with Virological Suppression of HIV Viral Load in Patients on Antiretroviral Therapy in Conakry, Guinea. Central African Journal of Public Health, 8(2), 22-27. https://doi.org/10.11648/j.cajph.20220802.11
ACS Style
Alimou Camara; Penda Maladho Diallo; Mamadou Bobo Diallo; Talla Nioké; Adama Cissé, et al. Factors Associated with Virological Suppression of HIV Viral Load in Patients on Antiretroviral Therapy in Conakry, Guinea. Cent. Afr. J. Public Health 2022, 8(2), 22-27. doi: 10.11648/j.cajph.20220802.11
AMA Style
Alimou Camara, Penda Maladho Diallo, Mamadou Bobo Diallo, Talla Nioké, Adama Cissé, et al. Factors Associated with Virological Suppression of HIV Viral Load in Patients on Antiretroviral Therapy in Conakry, Guinea. Cent Afr J Public Health. 2022;8(2):22-27. doi: 10.11648/j.cajph.20220802.11
Share This Article
Twitter
Linked In
Facebook
Copy
Download@article{10.11648/j.cajph.20220802.11,
author = {Alimou Camara and Penda Maladho Diallo and Mamadou Bobo Diallo and Talla Nioké and Adama Cissé and Mamadou Alpha Sylla and Gobounet Lamah and Mamady Diakité and Amadou Sadio Bah and Mamadou Bhoye Keita and Keita Alpha Kabinet Keita and Mamoudou Condé and Kaba Kourouma and Robert Camara and Youssouf Koita and Magassouba Fodé Bangaly and Alioune Camara and Abdoulaye Touré},
title = {Factors Associated with Virological Suppression of HIV Viral Load in Patients on Antiretroviral Therapy in Conakry, Guinea},
journal = {Central African Journal of Public Health},
volume = {8},
number = {2},
pages = {22-27},
doi = {10.11648/j.cajph.20220802.11},
url = {https://doi.org/10.11648/j.cajph.20220802.11},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.cajph.20220802.11},
abstract = {Viral load testing is a key indicator for assessing ART success and diagnosing drug resistance in people living with HIV/AIDS on antiretroviral therapy. This study aimed to assess virological suppression among people living with HIV / AIDS on antiretroviral therapy in Guinea. This was a three years descriptive cross-sectional that involved adult HIV-positive patients treated in different sites in Conakry. The study population consisted of patients living with HIV/AIDS, followed up at Conakry ART care and treatment sites, samples collected from the study population were sent to the National Institute of Public Health for viral load testing between January 2018 and June 2021. The viral load was quantified by the Generic Biocentric technique and the detection threshold set at 350 copies/ml. Factors associated with virological suppression were analysed by univariate or multivariate logistic regression. Statistical analysis were performed by R software version R4.0.3. A total of 9815 samples were collected and viral load data analyzed at the national public health laboratory. The sample was dominated by women (72%), with an average age of 29. Of these, 6,706 (68%) of people on ART had viral load suppression. The univaried analysis showed that women were (22%) more likely to have VL suppression (p-value < 0.001) moreover, the chance for all HIV-positive people on treatment to achieve viral load suppression was related to the length of treatment. The results of this study show viral load suppression greater than 68%. The length of antiretroviral therapy, female gender, and advancing age of PLHIV were associated with VL suppression. Targeted awareness raising actions must be undertaken with patients who have an important risk.},
year = {2022}
}
TY - JOUR T1 - Factors Associated with Virological Suppression of HIV Viral Load in Patients on Antiretroviral Therapy in Conakry, Guinea AU - Alimou Camara AU - Penda Maladho Diallo AU - Mamadou Bobo Diallo AU - Talla Nioké AU - Adama Cissé AU - Mamadou Alpha Sylla AU - Gobounet Lamah AU - Mamady Diakité AU - Amadou Sadio Bah AU - Mamadou Bhoye Keita AU - Keita Alpha Kabinet Keita AU - Mamoudou Condé AU - Kaba Kourouma AU - Robert Camara AU - Youssouf Koita AU - Magassouba Fodé Bangaly AU - Alioune Camara AU - Abdoulaye Touré Y1 - 2022/03/03 PY - 2022 N1 - https://doi.org/10.11648/j.cajph.20220802.11 DO - 10.11648/j.cajph.20220802.11 T2 - Central African Journal of Public Health JF - Central African Journal of Public Health JO - Central African Journal of Public Health SP - 22 EP - 27 PB - Science Publishing Group SN - 2575-5781 UR - https://doi.org/10.11648/j.cajph.20220802.11 AB - Viral load testing is a key indicator for assessing ART success and diagnosing drug resistance in people living with HIV/AIDS on antiretroviral therapy. This study aimed to assess virological suppression among people living with HIV / AIDS on antiretroviral therapy in Guinea. This was a three years descriptive cross-sectional that involved adult HIV-positive patients treated in different sites in Conakry. The study population consisted of patients living with HIV/AIDS, followed up at Conakry ART care and treatment sites, samples collected from the study population were sent to the National Institute of Public Health for viral load testing between January 2018 and June 2021. The viral load was quantified by the Generic Biocentric technique and the detection threshold set at 350 copies/ml. Factors associated with virological suppression were analysed by univariate or multivariate logistic regression. Statistical analysis were performed by R software version R4.0.3. A total of 9815 samples were collected and viral load data analyzed at the national public health laboratory. The sample was dominated by women (72%), with an average age of 29. Of these, 6,706 (68%) of people on ART had viral load suppression. The univaried analysis showed that women were (22%) more likely to have VL suppression (p-value < 0.001) moreover, the chance for all HIV-positive people on treatment to achieve viral load suppression was related to the length of treatment. The results of this study show viral load suppression greater than 68%. The length of antiretroviral therapy, female gender, and advancing age of PLHIV were associated with VL suppression. Targeted awareness raising actions must be undertaken with patients who have an important risk. VL - 8 IS - 2 ER -
Information
Email: